Results 61 to 70 of about 6,619 (182)
Plant‐derived nanovesicles (PDNVs) are naturally secreted by fruit, vegetables, seeds, leaves and other natural sources. Used as drug delivery systems, they can combine intrinsic therapeutic activity, enhanced skin permeation and cargo‐carrying capacity, suitable for dermatological and cosmetic applications including hydration, antioxidant/anti ...
Dorotea Fiore +5 more
wiley +1 more source
Tolvaptan for hyponatremia with preserved sodium pool in critically ill patients [PDF]
Additional file 1. Table S1. Baseline characteristics and primary and secondary outcomes in patients receiving either 7.5 or 15 mg of Tolvaptan. Table S2. Changes in electrolytes, hemodynamic and biochemistry parameters before and after administration of
M. Taverna +26 more
core +1 more source
Severe tolvaptan-associated hyperglycemia: a case report
Background Tolvaptan-associated hyperglycemia has rarely been described in literature. Case presentation A 95-year-old East Asian (Chinese) male patient with hyponatremia started on tolvaptan treatment at a dosage of 15 mg per day.
Huihuan Sun +5 more
doaj +1 more source
Tolvaptan for paraneoplastic SIADH in small cell lung cancer: a scoping review
Background: Hyponatremia due to the syndrome of inappropriate antidiuretic hormone (SIADH) occurs in approximately 25 % of patients with small cell lung cancer (SCLC). Tolvaptan has emerged as a promising option to treat SIADH in such patients.
Victoria L. Cammann +3 more
doaj +1 more source
Abstract Introduction Fluid restriction is the current first‐line therapy for hyponatremia induced by the syndrome of inappropriate antidiuresis (SIAD), yet up to 50% of patients do not achieve an adequate plasma sodium correction. Reported predictors of nonresponse include urine osmolality >500 mOsm/kg, the Furst ratio >1 [(UNa + UK)/(PNa)], urine ...
Michelle Patricia Müller +5 more
wiley +1 more source
Objective: Tolvaptan, a vasopressin V2 receptor antagonist, is an oral diuretic. Patients with terminal cancer develop marked fluid retention, and oral diuretics other than tolvaptan have been used as treatments without clear therapeutic effects. Herein,
Norimasa Tsuzuki +4 more
doaj +1 more source
An Investigation of the Factors Reducing the Use of Hospital Services: A Systematic Review
ABSTRACT Background and Aims Hospital service utilization has declined in many health systems due to policy shifts, limited resources, and alternative care approaches. This study aimed to systematically review the factors contributing to a reduction in the use or volume of hospital services.
Sedighe Sadat Tabatabaei Far +3 more
wiley +1 more source
Objectives: To assess the efficacy of tolvaptan in acute heart failure with hyponatremia using a randomized double-blinded placebo-controlled study design. Background: Tolvaptan is a selective vasopressin receptor 2 antagonist.
Elangovan Shanmugam +7 more
doaj +1 more source
ABSTRACT Background Sarcopenia is common in cirrhosis and is associated with poor outcomes. We aimed to identify factors associated with longitudinal skeletal muscle loss and to explore estimation of future L3 skeletal muscle index (L3‐SMI) using routinely available clinical variables. Methods This retrospective longitudinal study included 175 patients
Suguru Miida +14 more
wiley +1 more source
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic disorder and an important cause of end stage renal disease (ESRD).
Anish A. Kanhai (14456670) +5 more
core +1 more source

